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The Next Decade: A Shifting Focus*
Henry Spira
Animal Rights International

This World Congress represents a sea change, a tum toward the practical ·and the do-able. An added
dimension is the focus on public policy, that is, developing optimal scenarios for regulatory agencies to
accept viable alternatives as replacements for traditional animal tests. Congratulations to Alan Goldberg
for bringing together global representatives from the corporate, regulatory, scientific, academic, high tech,
and activist sectors, and for providing an environment conducive to sharing information and ideas.
This World Congress builds on earlier initiatives that legitimized and institutionalized the concept of
alternatives. This mainstreaming of alternatives has already led, according to Dr. Andrew Rowan of Tufts
University, to an estimated 38-50% reduction in animal use over the past decade. Major corporations
such as Avon, Bristol-Myers Squibb, Colgate, Hoffman-LaRoche, Johnson & Johnson, L'Oreal, Mobil,
Procter & Gamble, and Unilever are using in vitro systems for their inhouse research and development
(R&D) and questioning routine traditional practices. The corporate sector, bioresearch entrepreneurs, and
regulators are realizing the great promise in alternatives: that they are faster, cheaper, and more
predictive. And now the focus is evolving from R&D to closures with timetables.
Enormous strides have been made in the new discipline of in vitro toxicology, but this success remains to
be translated into regulatory policy decisions. Until recently, alternatives evolved in a regulatory vacuum,
without the necessary involvement of the global regulatory sector, from the ground up. A workshop on
alternatives to eye irritation testing sponsored by the Interagency Regulatory Alternatives Group (IRAG)
and this Congress spotlights the increasing involvement of the regulatory community with alternatives.
The European Community recognizes that the validation of potential alternatives is the key to their
application and use; Accordingly, they have established the European Center for the Validation of
Alternative Methods (ECVAM) in Ispra, Italy, to coordinate the validation of alternatives. ECVAM, guided
by Dr. Michael Balls, is becoming a center for information exchange, promoting dialogue among
legislators, industry, scientists, consumer and animal advocates. Global commerce makes international
harmonization crucial.
With their recent congressional mandate to implement alternatives, U.S. regulators and the National
Institute for Environmental Health Sciences are also moving forward in joint efforts with both industry and
the international regulatory community.
After a decade of brilliant science, now there is a need for aggressive implementation and global
regulatory harmonization. And we must maintain the momentum and the energy that reduced the use of
lab animals by as much as 50%. This massive reduction was made possible by the "three R's," methods,
which Replace the use of animals, Reduce the number of animals used, or Refine procedures to reduce
pain and distress; and by the "zero based" concept, which calls for all animal research/testing/ education
programs to be re-examined from ground zero, so as not to repeat mindlessly tomorrow what was done
yesterday. This is already being done by forward-looking researchers and it needs to become the norm
throughout the corporate, academic, and governmental sectors.

The ability to be flexible and adapt to emerging and changing circumstances is what has made the
difference to date. It should continue to make the difference in the future.
This World Congress has been dedicated to Gerhard Zbinden. We can pay no greater homage to this
sensitive and brilliant scientist than to complete what he pioneered. It seems to me that to realize Gerhard
Zbinden's vision we need clear goals, and blueprints with timeframes and benchmarks. In addition there
must be an incentive. We must be as motivated about implementation as we have been about R&D. One
of the motivations in this instance is to make our lives worthwhile. All of us want our lives to amount to
more than consuming resources and generating garbage. All of us want to be able to look back and know
that we have been able to help enhance the lives of others: to reduce substantially the pain and suffering
of our fellow inhabitants.

* Text of a speech to the World Congress on Alternatives and Animal Use in the Life Sciences: Education,
Research and Testing. Nov. 14-19, 1994, Baltimore, MD.
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